The recent surge in investments into niche pharmaceutical companies, particularly those focusing on groundbreaking therapies and difficult drug development programs, has ブックメーカー fueled what some are calling "High Roller Pharma." While the possibility for blockbuster treatments and impressive returns is clear, the linked risks are also